Результаты поиска

Frontiers in Antibody-Drug Conjugates: Mechanisms, Design Innovations, and Clinical Applications in Targeted Cancer Therapy.

Antibody-drug conjugates (ADCs) represent a transformative class of targeted therapies designed to deliver potent cytotoxic agents specifically to tumor cells, minimizing systemic toxicity. This review provides a comprehensive overview of ADCs, detailing their mechanisms of action, design strategies, and clinical advancements. ADCs utilize monoclonal antibodies to selectively bind tumor-associated antigens, enabling the precise delivery of toxic payloads to cancer cells. The review explores the critical components of ADCs, including the antibody, linker, and payload, and highlights how these e

Совпадение в полном тексте источника
… Dato-DXd was compared head-to-head with docetaxel in the Phase III TROPION-Lung01 study for pretreated advanced or metastatic NSCLC patients. … In a Phase III study, Sacituzumab Govitecan (SG) did not significantly improve OS compared to docetaxel in the overall population of pretreated metastatic NSCLC. …

Navigating antibody‒drug conjugates (ADCs): from metastatic to early breast cancer treatment strategies.

We are currently living in the era of precision medicine, and antibody‒drug conjugates (ADCs) represent promising advancements in targeted cancer therapy. While several ADCs have been investigated over the years, only three have gained FDA approval for breast cancer (BC): ado-trastuzumab emtansine (T-DM1/Kadcyla), trastuzumab deruxtecan (T-DXd/Enhertu), and sacituzumab govitecan (SG/Trodelvy). This review focuses on the three approved ADCs for BC, reviewing the trials that led to their approval and detailing the ongoing trials testing their clinical efficacy and safety profiles. We examine ong

Совпадение в полном тексте источника
… ; TCHP docetaxel, carboplatin, trastuzumab, pertuzumab; PCHP paclitaxel, carboplatin, trastuzumab, pertuzumab; MTD maximum tolerated dose; RDE recommended dose escalation; RP2D recommended phase 2 dose; Bi bicompartmental; iBCSF invasive breast cancer-free survival; LRRFI locoregional recurrence-free … ; TCHP docetaxel, carboplatin, trastuzumab, pertuzumab; PCHP paclitaxel, carboplatin, trastuzumab, pertuzumab; MTD maximum tolerated dose; RDE recommended dose escalation; RP2D recommended phase 2 dose; Bi bicompartmental; iBCSF invasive breast cancer-free survival; LRRFI locoregional recurrence-free …

34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1 : National Harbor, MD, USA. 6-10 November 2019.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Solitary Giant Primary Gastric Plasmacytoma Mimicking Gastric Adenocarcinoma In Situ.

A solitary extraosseous plasmacytoma is a rare type of plasma cell neoplasm. Its occurrence in the stomach is particularly unusual and can easily be mistaken for more common types of tumors. We describe a case involving a solitary extraosseous plasmacytoma in a patient who experienced weight loss as the sole symptom. Initially, the condition was misdiagnosed as gastric adenocarcinoma based on endoscopic biopsy results, leading to a gastrectomy after neoadjuvant chemotherapy. Subsequent examination of the pathological specimen revealed the presence of plasma cell neoplasia alongside a gastric a

Совпадение в полном тексте источника
… The patient underwent a perioperative FLOT chemotherapy (docetaxel, oxaliplatin, and fluorouracil/leucovorin) followed by gastrectomy. …

PD 1 checkpoint inhibition in solid organ transplants: 2 sides of a coin - case report.

BACKGROUND: The management of malignancy post kidney transplantation includes reduction in immunosuppression and referral to an oncologist management of their malignancy. Recent advances in oncology have resulted in the approval of several classes of drugs with immune-modulatory activity. However, activation of the immune system against malignant cells may precipitate allograft rejection in solid organ transplant recipients. CASE PRESENTATION: Herein we present a case of acute kidney allograft rejection in a 50 year old man following administration of the novel immune-modulatory agent nivolum

Совпадение в полном тексте источника
… Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung Cancer. N Engl J Med. 2015;373:123–135. doi: 10.1056/NEJMoa1504627. 2. Weber JS, D’Angelo SP, Minor D, et al. …

How to Treat Melanoma? The Current Status of Innovative Nanotechnological Strategies and the Role of Minimally Invasive Approaches like PTT and PDT.

Melanoma is the most aggressive type of skin cancer, the incidence and mortality of which are increasing worldwide. Its extensive degree of heterogeneity has limited its response to existing therapies. For many years the therapeutic strategies were limited to surgery, radiotherapy, and chemotherapy. Fortunately, advances in knowledge have allowed the development of new therapeutic strategies. Despite the undoubted progress, alternative therapies are still under research. In this context, nanotechnology is also positioned as a strong and promising tool to develop nanosystems that act as drug ca

Совпадение в полном тексте источника
… Liu et al., also proposed this type of system for drug delivery of docetaxel (DTX) [ 131 ]. Once again, the nanoformulation of the compound aimed to overcome its lower aqueous solubility. … Abbreviations: CTX, cyclophosphamide; DLS, dynamic light scattering; DTIC, dacarbazine; DTX, docetaxel; GMS, glycerol monostearate; HPLC, high performance liquid chromatography; i.p., intraperitoneal; IPM, isopropyl myristate; i.v., intravenous; LEM2, carbaldehyde dimethoxyxanthone; MTT, dimethylthiazol …

Clinical Efficacy of a Novel Therapeutic Principle, Anakoinosis.

Classic tumor therapy, consisting of cytotoxic agents and/or targeted therapy, has not overcome therapeutic limitations like poor risk genetic parameters, genetic heterogeneity at different metastatic sites or the problem of undruggable targets. Here we summarize data and trials principally following a completely different treatment concept tackling systems biologic processes: the principle of communicative reprogramming of tumor tissues, i.e., anakoinosis (ancient greek for communication), aims at establishing novel communicative behavior of tumor tissue, the hosting organ and organism via re

Совпадение в полном тексте источника
… . | 777 | Chemo-immune therapy | • Low versus normal vitamin D levels in serum | - | Low serum vitamin D levels are associated with inferior survival in follicular lymphoma | Kelly et al., 2015 PROSTATE CANCER (RANDOMIZED) Androgen-independentprostate cancer | 70 | Docetaxel | • Doxercalciferol | - | … Randomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer. Clin. Cancer Res. 14, 2437–2443. 10.1158/1078-0432.CCR-07-4274 Aviles A., Neri N., Fernandez-Diez J., Silva L., Nambo M.-J. (2015). …

Anti-Cancer Stem-like Cell Compounds in Clinical Development - An Overview and Critical Appraisal.

Cancer stem-like cells (CSC) represent a subpopulation of tumor cells with elevated tumor-initiating potential. Upon differentiation, they replenish the bulk of the tumor cell population. Enhanced tumor-forming capacity, resistance to antitumor drugs, and metastasis-forming potential are the hallmark traits of CSCs. Given these properties, it is not surprising that CSCs have become a therapeutic target of prime interest in drug discovery. In fact, over the last few years, an enormous number of articles describing compounds endowed with anti-CSC activities have been published. In the meanwhile,

Совпадение в полном тексте источника
… NCT01255800 (phase I): with cetuximab in recurrent head and neck cancer | ( 69 ) ( 70 ) Anti-RSPO3 mAb: OMP-131R10 | NCT02482441 (phase Ia/Ib): in combination with chemotherapy in previously treated metastatic CRC | ( 71 ) Anti-Frizzled receptors mAB: vantictumab/OMP-18R5 | NCT01957007 (phase Ib): with docetaxel … In metastatic docetaxel-resistant prostate cancer cell lines, it reduced FAK phosphorylation in the resistant cells without affecting cell viability and overcame the chemoresistant phenotype ( 134 ). …

Blastic Plasmacytoid Dendritic Cell Neoplasm: A Case Report.

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an uncommon hematological tumor originating from the precursor of plasmacytoid dendritic cells (pDCs) with a persistent and progressive course of illness. Despite being an aggressive disease BPDCN has an initial indolent course manifested as skin lesions. Alongside or following the skin lesion, the extra-cutaneous manifestation develops and includes lymphadenopathy, splenomegaly, and hepatomegaly. The BPDCN diagnosis is mainly based on the immunophenotype.  Herein, we report the case of a 72-year-old male patient who presented with a hist

Совпадение в полном тексте источника
… Single agents demonstrated some efficacy in BPDCN including pralatrexate, bendamustine, or gemcitabine/docetaxel combinations. Although the results were encouraging, these trials were only conducted on a small number of individuals, and they need to be confirmed in larger trials [ 1 , 17 , 20 ]. …

Skeletal-related events and overall survival of patients with bone metastasis from nonsmall cell lung cancer - A retrospective analysis.

Because of improving treatments and survival, 40% to 58% of patients with bone metastases from nonsmall cell lung cancer (NSCLC) will suffer from at least one skeletal-related event (SRE), affecting their quality of life, but the natural history of SRE is poorly understood. The study aimed to examine the factors involved in SRE-free survival (SRS) and overall survival (OS) of patients with NSCLC and bone metastases.This was a retrospective study of 211 patients with bone metastasis from NSCLC and treated at the Tumor Hospital Affiliated to Harbin Medical University between January 2007 and Jan

Совпадение в полном тексте источника
… Feasibility study of zoledronic acid plus cisplatin-docetaxel as first-line treatment for advanced non-small cell lung cancer with bone metastases. Anticancer Res 2012;32:4131–5. [17] Tsuya A, Kurata T, Tamura K, et al. Skeletal metastases in non-small cell lung cancer: a retrospective study. …

Keyword Index for Volume 103

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… carcinoma 1115 disabled-2 1716 discriminative markers 1048 discriminatory power 423 disease-specific survival 899, 1831 dissemination 1706 distant metastasis 715 distress screening 1489 DNA cytometry 1432 DNA double-strand breaks 1822 DNA repair 36, 362, 1822 DNA replication licensing 701 DNP 1400 docetaxel …

Biological Nanocarriers in Cancer Therapy: Cutting Edge Innovations in Precision Drug Delivery.

Cancer is a highly detrimental and fatal illness that poses a significant threat to human well-being. The pattern of cancer treatment is continuously being optimized by the advancement of old treatment approaches and the invention of novel treatment modes. Nanotechnology-based approaches are emerging as powerful candidates in the development of these advanced methods for treating tumors. This article provides a concise overview of nanotechnology for cancer or cancer nanomedicine and its applications. In light of prevalent issues, such as inadequate precision in targeting initial chemotherapy d

Совпадение в полном тексте источника
… Product | Nanoparticle Material | Company | Active Ingredient | Clinical Trial Number | Indication | References Docetaxel-PNP | Polymeric nanoparticles | Samyang Biopharmaceuticals Corporation (Gyeonggi-do, South Korea) | Docetaxel | NCT01103791 | Advanced solid malignancies | [ 41 , 45 , 46 ] ABT-888 …

Mechanisms of resistance to antibody-drug conjugates in cancer therapy: molecular basis and therapeutic strategies.

Antibody-drug conjugates (ADCs) have emerged as a transformative class in oncology, integrating the target specificity of monoclonal antibodies with the potent cytotoxicity of small-molecule payloads. By harnessing tumor-specific antigen recognition, ADCs enable the selective delivery of chemotherapeutic agents, thereby enhancing therapeutic efficacy while reducing systemic toxicity. Their clinical success across both hematologic malignancies and solid tumors underscores their potential to redefine targeted cancer therapy. However, the clinical durability of ADCs is increasingly undermined by

Совпадение в полном тексте источника
… A particularly exciting example is a C-X-C chemokine receptor type 4 (CXCR4) antagonist peptide-docetaxel conjugate, which self-assembles into nanoparticles targeting CXCR4-overexpressing metastatic tumors. … Self-assembly of CXCR4 antagonist peptide-docetaxel conjugates for breast tumor multi-organ metastasis inhibition. Acta Pharm Sin B. 2023;13:3849–61. doi: 10.1016/j.apsb.2023.03.024. 93. Kong FE, Li GM, Tang YQ, et al. …

The efficacy and safety of exercise regimens to mitigate chemotherapy cardiotoxicity: a systematic review and meta-analysis of randomized controlled trials.

BackgroundCardiotoxicity is one of the most common adverse events of the chemotherapy. Physical exercise was shown to be cardioprotective. We aim to estimate the efficacy and safety of exercise in cancer patients receiving cardiotoxic chemotherapy.MethodsWe conducted a systematic review and meta-analysis of randomized controlled trials (RCTs), which were retrieved by systematically searching PubMed, Web of Science, SCOPUS, Cochrane, Clinical Trials.gov, and MedRxiv through July 17th, 2023. We used RevMan V. 5.4 to pool dichotomous data using risk ratio (RR) and continuous data using mean diffe

Совпадение в полном тексте источника
… resistance exercise, and flexibility training) | 12 | 2 to 3 | 65 | Moderate-to-high–intensity exercise | Usual care | Chemotherapy every 3 weeks with CEF for 6 cycles (cyclophosphamide 500 mg/m2, epirubicin 75 mg/m2, and 5-FU 500 mg/m2) or doxorubicin plus cyclophosphamide for 4 cycles followed by docetaxel … for 4 cycles (doxorubicin 60 mg/m2, cyclophosphamide 600 mg/m2 and docetaxel 60 mg/m2 | Breast cancer stage I–III | 76% | The change in left LVEF | 12 months Foulkes et al. 2023 [ 10 ] (The BREXIT) | Open-labelled single center Randomized Controlled trial | Australia | 104 | Aerobic and resistance Exercise …

The dark side of immunotherapy.

Immunotherapy has broadened the therapeutic scope and response for many cancer patients with drugs that are generally of higher efficacy and less toxicity than prior therapies. Multiple classes of immunotherapies such as targeted antibodies and immune checkpoint inhibitors (ICI), cell-based immunotherapies, immunomodulators, vaccines, and oncolytic viruses have been developed to help the immune system target and destroy malignant tumors. ICI targeting programmed cell death protein-1 (PD-1) or its ligand (PD-L1) are among the most effective immunotherapy agents and are a major focus of current

Совпадение в полном тексте источника
… Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet 2016;387:1540-50. 10.1016/S0140-6736(15)01281-7 30. Paz-Ares L, Luft A, Vicente D, et al. … Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015;373:1627-39. 10.1056/NEJMoa1507643 38. De Velasco G, Je Y, Bossé D, et al. Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1/PD-L1 inhibitors in cancer patients. …

Mechanisms of Cancer Resistance to Immunotherapy.

Over the last decade, based on the extensive development of preclinical animal studies and clinical trials, the efficacy, and mechanisms of immunotherapy have been fully explored. Significant and lasting clinical responses with immunotherapy provide a new breakthrough treatment for a variety of refractory cancer histologies, which gradually change the treatment pattern of tumors. However, although immune checkpoint inhibitor drugs are promising for achieving longer-term efficacy, their benefits in the overall population are still very low, such as low frequency of response in some common tumor

Совпадение в полном тексте источника
… Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. (2015) 373:1627–39. 10.1056/NEJMoa1507643 58. Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, et al. … Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. (2016) 387:1540–50. 10.1016/S0140-6736(15)01281-7 59. Gainor JF, Shaw AT, Sequist LV, Fu X, Azzoli CG, Piotrowska Z, et al. …

G Protein-Coupled Receptor Signaling: Implications and Therapeutic Development Advances in Cancers.

G protein-coupled receptors (GPCRs) are the largest and most diverse class of membrane proteins, mediating cellular responses to a wide range of extracellular stimuli. GPCRs initiate complex intracellular signaling networks that regulate vital physiological functions and are associated with numerous diseases, including various types of cancer. Their conserved seven-transmembrane (7TM) structure enables these signaling networks by allowing interactions with multiple ligands and intracellular effectors. In several types of tumors, abnormal GPCR signaling promotes carcinogenesis by supporting imm

Metabolic Reprogramming of Cancer Cells and Therapeutics Targeting Cancer Metabolism.

BackgroundCancer metabolism is a field focused on the unique alterations in metabolic pathways that occur in cancer cells, distinguishing them from the metabolic processes in normal cells.MethodsAn extensive review of the current literature on the metabolic adaptation of cancer cells was carried out in the current study.ResultsThe rapidly proliferating cells require high levels of molecules, such as glucose, amino acids, lipids, and nucleotides, along with increased energy demand (ATP). These requirements are met through alterations in the processes involving glucose, amino acid, lipid, and nu

Совпадение в полном тексте источника
… This increased activity promotes resistance against docetaxel through increased expression of the oncogene, Yes‐associated protein (YAP). … Research has demonstrated that the combined use of valproic acid and simvastatin (an HMG‐CoA reductase inhibitor) can sensitize prostate carcinoma to docetaxel by targeting cancer stem cells through YAP inhibition [ 127 ]. …

FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from Early 2011 to the End of 2021.

Solid cancers are the most common types of cancers diagnosed globally and comprise a large number of deaths each year. The main challenge currently in drug development for tumors raised from solid organs is to find more selective compounds, which exploit specific molecular targets. In this work, the small molecule drugs registered by the Food and Drug Administration (FDA) for solid cancers treatment between 2011 and 2022 were identified and analyzed by investigating a type of therapy they are used for, as well as their structures and mechanisms of action. On average, 4 new small molecule agent

Совпадение в полном тексте источника
… It had its first approval already in 2011, in combination with prednisone for late-stage castrate-resistant prostate cancer (CRPC) in patients who previously received docetaxel chemotherapy, but FDA only granted its full approval on 10 December 2012 [ 171 ]. … The first approval of enzalutamide was obtained for the treatment of patients with metastatic CRPC who have previously been treated with docetaxel . …

Целевые стратегии лечения рака цвета кожи: изучение использования аптемеров и золотых нанопчастей.

Рак цвета кожи (КЗК) является второй ведущей причиной смертности от рака и является причиной ~10% из всех случаев рака. По оценкам, во всем мире случаи, связанные с КПР 1.9 million и 930,000 смертями в 2022. Несмотря на расширение доступа к обследованиям и лечению в рамках КПР, ожидается, что показатели смертности резко возрастут в районах с низким уровнем ресурсов, что подчеркивает настоятельную необходимость принятия новаторских мер по лечению в рамках КПР. Текущая химиотерапия создает проблемы, такие, как плохая биодоступность, резистентность к многочисленным лекарствам и негативные побочны

Совпадение в полном тексте источника
… Anticancer drugs used in CRC treatment include dox, docetaxel, leucovorin, 5-FU, and irinotecan [ 4 ]. … In their targeting roles, aptamers have been conjugated with anticancer drugs such as docetaxel [ 150 ], dox [ 151 ] and gemcitabine [ 145 ] to enhance drug biodistribution and efficacy. …